Welcome to Arctom, sign up to enjoy up to 20% OFF
- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1491917-83-9] Sacituzumabgovitecan
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-132254 |
| Brand: | MCE |
| CAS: | 1491917-83-9 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 489.57 |
| Molecular Formula | C25H31N9O2 |
| SMILES | [Sacituzumab govitecan] |
For research use only. We do not sell to patients.
Summary
In Vivo
Sacituzumab govitecan (IMMU-132) (17.5 mg/kg; twice weekly for 4 weeks) results in significant anti-tumor effects in mice bearing human gastric cancer xenografts [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04230109 | Aditya Bardia|Gilead Sciences|Massachusetts General Hospital |
Invasive Breast Cancer|Triple Negative Breast Cancer|ER-Negative Breast Cancer|PR-Negative Breast Cancer|HER2-negative Breast Cancer
|
July 7, 2020 | Phase 2 |
| NCT05609968 | Merck Sharp & Dohme LLC|Gilead Sciences |
Carcinoma, Non-Small-Cell Lung
|
December 16, 2022 | Phase 3 |
| NCT04039230 | Massachusetts General Hospital|Pfizer |
Breast Cancer
|
October 9, 2019 | Phase 1|Phase 2 |
| NCT03337698 | Hoffmann-La Roche |
Carcinoma, Non-Small-Cell Lung
|
January 2, 2018 | Phase 1|Phase 2 |
| NCT04958785 | Gilead Sciences |
Triple-Negative Breast Cancer
|
December 14, 2021 | Phase 2 |
| NCT03725761 | University of Wisconsin, Madison|National Cancer Institute (NCI)|Gilead Sciences |
Prostate Cancer
|
October 24, 2018 | Phase 2 |
| NCT05581589 | University of Washington|Gilead Sciences |
Muscle Invasive Bladder Carcinoma|Stage II Bladder Cancer AJCC v8|Stage IIIA Bladder Cancer AJCC v8
|
November 2022 | Phase 2 |
| NCT03424005 | Hoffmann-La Roche|Seagen Inc.|Gilead Sciences |
Triple Negative Breast Cancer
|
April 2, 2018 | Phase 1|Phase 2 |
| NCT04251416 | Alessandro Santin|Gilead Sciences|Yale University |
Endometrial Carcinoma
|
February 25, 2020 | Phase 2 |
| NCT03971409 | Hope Rugo, MD|Translational Breast Cancer Research Consortium|Hoosier Cancer Research Network|Array BioPharma|Pfizer|Breast Cancer Research Foundation|Johns Hopkins University|University of California, San Francisco |
Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Invasive Breast Carcinoma|Recurrent Breast Carcinoma|Triple-Negative Breast Carcinoma|Unresectable Breast Carcinoma
|
July 8, 2019 | Phase 2 |
| NCT04639986 | Everest Medicines|Iqvia Pty Ltd|Medidata Solutions|Parexel |
Metastatic Breast Cancer
|
November 23, 2020 | Phase 3 |
| NCT02161679 | Gilead Sciences |
Triple-negative Breast Cancer
|
August 2016 | Phase 2 |
| NCT04826341 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
HRD Cancer|SCLC|Advanced Solid Tumors
|
September 20, 2021 | Phase 1|Phase 2 |
| NCT04448886 | Ana C Garrido-Castro|Merck Sharp & Dohme LLC|Gilead Sciences|Dana-Farber Cancer Institute |
Invasive Breast Cancer|Metastatic Breast Cancer|HR-Positive Breast Cancer|HER2-negative Breast Cancer
|
September 23, 2020 | Phase 2 |
| NCT04434040 | Dana-Farber Cancer Institute|Genentech, Inc.|Stand Up To Cancer |
Breast Cancer|Triple Negative Breast Cancer|Residual Cancer|Circulating Tumor DNA
|
July 2, 2020 | Phase 2 |
| NCT05552001 | UNICANCER|Gilead Sciences |
Triple Negative Breast Cancer|Metastatic Breast Cancer
|
January 1, 2023 | Phase 3 |
| NCT03992131 | Clovis Oncology, Inc.|Gilead Sciences |
Ovarian Cancer|Triple-negative Breast Cancer|Urothelial Carcinoma|Solid Tumor
|
June 28, 2019 | Phase 1|Phase 2 |
| NCT04454437 | Everest Medicines|IQVIA RDS (Shanghai) Co., Ltd.|Medidata Solutions|Q Squared Solutions (Beijing) Co., Ltd|Parexel |
Metastatic Triple-negative Breast Cancer
|
October 23, 2020 | Phase 2 |
| NCT03869190 | Hoffmann-La Roche|Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas |
Urothelial Carcinoma|Bladder Cancer
|
June 1, 2019 | Phase 1|Phase 2 |
| NCT04320693 | Gilead Sciences |
Metastatic Triple-Negative Breast Carcinoma
|
||
| NCT04863885 | H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb|Gilead Sciences |
Metastatic Urothelial Carcinoma
|
April 30, 2021 | Phase 1|Phase 2 |
| NCT05520723 | MedSIR|Gilead Sciences |
Triple Negative Breast Cancer|Breast Cancer
|
January 11, 2023 | Phase 2 |
| NCT05327530 | EMD Serono Research & Development Institute, Inc.|Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics|EMD Serono |
Locally Advanced or Metastatic Urothelial Carcinoma
|
August 17, 2022 | Phase 2 |
| NCT04468061 | Dana-Farber Cancer Institute|Gilead Sciences|Merck Sharp & Dohme LLC |
Breast Cancer|Triple Negative Breast Cancer|PD-L1 Negative
|
July 20, 2020 | Phase 2 |
| NCT05226117 | IRCCS San Raffaele|High Research |
Urothelial Carcinoma
|
November 29, 2021 | Phase 2 |
| NCT04559230 | The University of Texas Health Science Center at San Antonio |
Glioblastoma
|
January 6, 2022 | Phase 2 |
| NCT04595565 | German Breast Group|Gilead Sciences|Austrian Breast & Colorectal Cancer Study Group|Spanish Breast Cancer Research Group (GEICAM)|ETOP IBCSG Partners Foundation|Cancer Trials Ireland|UNICANCER |
HER2-negative Breast Cancer|Triple Negative Breast Cancer
|
October 28, 2020 | Phase 3 |
| NCT04647916 | Southwest Oncology Group|National Cancer Institute (NCI)|Gilead Sciences |
Anatomic Stage IV Breast Cancer AJCC v8|Invasive Breast Carcinoma|Metastatic HER2 Negative Breast Carcinoma|Metastatic Malignant Neoplasm in the Brain|Prognostic Stage IV Breast Cancer AJCC v8
|
December 15, 2020 | Phase 2 |
| NCT05143229 | University of Kansas Medical Center|Novartis Pharmaceuticals|Gilead Sciences |
Breast Cancer
|
March 28, 2022 | Phase 1 |
| NCT04986579 | Dana-Farber Cancer Institute|Paxman Coolers Limited|AstraZeneca|Eisai Inc.|Daiichi Sankyo, Inc.|Gilead Sciences |
Metastatic Breast Cancer|Chemotherapy-induced Alopecia
|
October 7, 2021 | Phase 2 |
| NCT03995706 | The University of Texas Health Science Center at San Antonio|Gilead Sciences |
Glioblastoma
|
July 17, 2019 | Early Phase 1 |
| NCT05332561 | German Cancer Research Center |
Early-stage Breast Cancer
|
December 2022 | Phase 2 |
| NCT04724018 | Dana-Farber Cancer Institute|Gilead Sciences |
Urothelial Cancer|Metastatic Urothelial Carcinoma|Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter|Bladder Cancer
|
May 20, 2021 | Phase 1 |
| NCT02574455 | Gilead Sciences |
Breast Cancer
|
November 7, 2017 | Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Store at 4°C, do not freeze
References
- [1] Cardillo TM, et al. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26(5):919-31.
- [2] Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) [published correction appears in Oncotarget. 2020 Mar 10;11(10):942]. Oncotarget. 2015;6(26):22496-22512.
Request a Quote
Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.
Information
Customer service
My account
Powered by Arctom
Copyright © 2021 Arctom. All rights reserved.